SEC Form 4 · accession 0001127602-15-013968
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John R Moore
Officer — VP, General Counsel
Period of report
Apr 1, 2015
Accepted (ET)
Apr 3, 2015 · 6:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 1, 2015 | A | 26,875 | $0.00 | A | 42,259 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $7.30 | Apr 1, 2015 | A | 161,250 | A | — | Apr 1, 2025 | Common Stock | 161,250 | 161,250 | D |
Explanation of responses
- F1Consists of Restricted Stock Units awarded to the reporting person for no additional cash consideration and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The units vest and will be settled in stock in four equal annual installments beginning on April 1, 2016.
- F2The option vests in four equal annual installments beginning April 1, 2016.